Search Results - Arjun Vasant Balar

Refine Results
  1. 1
    PD-1 and PD-L1 antibodies in cancer: current status and future directions

    PD-1 and PD-L1 antibodies in cancer: current status and future directions by Arjun Vasant Balar, Jeffrey S. Weber

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Prospective Pilot Study to Evaluate the Incremental Value of PET Information in Patients With Bladder Cancer Undergoing 18F-FDG Simultaneous PET/MRI

    Prospective Pilot Study to Evaluate the Incremental Value of PET Information in Patients With Bladder Cancer Undergoing 18F-FDG Simultaneous PET/MRI by Andrew B. Rosenkrantz, Kent Friedman, Fabio Ponzo, Roy A. Raad, Kimberly Jackson, William C. Huang, Arjun Vasant Balar

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

    The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients by Douglas M. Donnelly, Shirin Bajaj, Jae-Hong Yu, Miles Hsu, Arjun Vasant Balar, Anna C. Pavlick, Jeffrey S. Weber, Iman Osman, Judy Zhong

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

    BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma by Brian Labadie, Ping Liu, Riyue Bao, Michael Crist, Ricardo Fernandes, Laura Ferreira, Scott Graupner, Andrew Poklepovic, Ignacio Durán, Saman Maleki Vareki, Arjun Vasant Balar, Jason J. Luke

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer

    Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer by Arjun Vasant Balar, Andrea B. Apolo, Irina Ostrovnaya, Svetlana Mironov, Alexia Iasonos, A. Trout, Ashley Marie Regazzi, Ilana Garcia-Grossman, David Gallagher, Matthew I. Milowsky, Dean F. Bajorin

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

    Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status by Petros Grivas, Elizabeth R. Plimack, Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Joaquim Bellmunt, Thomas Powles, Noah M. Hahn, Ronald de Wit, Dean F. Bajorin, Misoo C. Ellison, Tara L. Frenkl, James Luke Godwin, Jacqueline Vuky

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Phase <scp>II</scp> study of everolimus in metastatic urothelial cancer

    Phase <scp>II</scp> study of everolimus in metastatic urothelial cancer by Matthew I. Milowsky, Gopa Iyer, Ashley Marie Regazzi, Hikmat Al‐Ahmadie, Scott R. Gerst, Irina Ostrovnaya, Lan L. Gellert, Rana Kaplan, Ilana Garcia-Grossman, Deepa Pendse, Arjun Vasant Balar, Anne Marie C. Flaherty, A. Trout, David B. Solit, Dean F. Bajorin

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

    Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study by Arjun Vasant Balar, Joaquim Bellmunt, Peter H. O’Donnell, Daniel Castellano, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R. Plimack, Noah M. Hahn, Ronald de Wit, Lei Pang, Mary J. Savage, Rodolfo F. Perini, Stephen J. O’Keefe, Dean F. Bajorin

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

    Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy by Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar, Bradley A. McGregor, Elisabeth I. Heath, Evan Y. Yu, Matthew D. Galsky, Noah M. Hahn, Elaina M. Gartner, Juan Pinelli, Shang-Ying Liang, Amal Melhem‐Bertrandt, Daniel P. Petrylak

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

    Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer by Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Savage, Xiao Fang, James Luke Godwin, Tara L. Frenkl, Blanca Homet Moreno, Ronald de Wit, Elizabeth R. Plimack

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Somatic mutation of fibroblast growth factor receptor‐3 (<i>FGFR3</i>) defines a distinct morphological subtype of high‐grade urothelial carcinoma

    Somatic mutation of fibroblast growth factor receptor‐3 (<i>FGFR3</i>) defines a distinct morphological subtype of high‐grade urothelial carcinoma by Hikmat Al‐Ahmadie, Gopa Iyer, Manickam Janakiraman, Oscar Lin, Adriana Heguy, Satish K. Tickoo, Samson W. Fine, Anuradha Gopalan, Ying‐Bei Chen, Arjun Vasant Balar, Jamie C. Riches, Bernard H. Bochner, Guido Dalbagni, Dean F. Bajorin, Victor E. Reuter, Matthew I. Milowsky, David B. Solit

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

    TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhi... by Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

    TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhi... by Yohann Loriot, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip L. Palmbos, Arjun Vasant Balar, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, M. Sierecki, Hao Zhou, Petros Grivas, Philippe Barthélémy, Scott T. Tagawa

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer

    Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer by Gopa Iyer, Hikmat Al‐Ahmadie, Nikolaus Schultz, Aphrothiti J. Hanrahan, Irina Ostrovnaya, Arjun Vasant Balar, Philip H. Kim, Oscar Lin, Nils Weinhold, Chris Sander, Emily C. Zabor, Manickam Janakiraman, Ilana Garcia-Grossman, Adriana Heguy, Agnès Viale, Bernard H. Bochner, Victor E. Reuter, Dean F. Bajorin, Matthew I. Milowsky, Barry S. Taylor, David B. Solit

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

    An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer by Thomas Powles, Danielle Carroll, Simon Chowdhury, Gwénaëlle Gravis, Florence Joly, Joan Carles, Aude Fléchon, Pablo Maroto, Daniel P. Petrylak, Frédéric Rolland, Natalie Cook, Arjun Vasant Balar, Srikala S. Sridhar, Matthew D. Galsky, Petros Grivas, Alain Ravaud, Robert J. Jones, Jan Cosaert, Darren Hodgson, Iwanka Kozarewa, Richard Mather, Robert McEwen, Florence Mercier, Dónal Landers

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up by Arjun Vasant Balar, Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Andrea Necchi, Daniel P. Petrylak, Elizabeth R. Plimack, Jin Xu, Kazuo Imai, Blanca Homet Moreno, Joaquim Bellmunt, Ronald de Wit, Peter H. O’Donnell

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials by Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel Ángel Climent, Daniel P. Petrylak, Jae‐Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O’Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun Vasant Balar, Daniel Castellano, Toni K. Choueiri, Stéphane Culine, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Rǎzvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicent... by Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, Jose Luis Pérez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer

    Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer by Gopa Iyer, Arjun Vasant Balar, Matthew I. Milowsky, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, William C. Huang, Samir S. Taneja, Michael Woods, Irina Ostrovnaya, Hikmat Al‐Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Tracy L. Rose, William Y. Kim, Brooke Kania, Mariel Elena Boyd, C Cipolla, Ashley Marie Regazzi, Daniela Delbeau, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, Dean F. Bajorin

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial by Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, Jose Luis Pérez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: